Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

被引：0
|
作者：
Stefania Bulotta
Marilena Celano
Giuseppe Costante
Diego Russo
机构：
[1] University “Magna Graecia” of Catanzaro,Department of Health Sciences
[2] Institut Jules Bordet Comprehensive Cancer Center,Endocrinology Clinic, Internal Medicine Department
来源：
Endocrine | 2016年 / 52卷
关键词：
Differentiated thyroid cancer; Radioiodine; Molecular targets; Re-differentiation strategies; Nanodevices;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.
引用
收藏
页码：214 / 221
页数：7
相关论文
共 50 条
  • [1] Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine
    Bulotta, Stefania
    Celano, Marilena
    Costante, Giuseppe
    Russo, Diego
    ENDOCRINE, 2016, 52 (02) : 214 - 221
  • [2] Radioiodine refractory differentiated thyroid cancer
    Jin, Yuchen
    Van Nostrand, Douglas
    Cheng, Lingxiao
    Liu, Min
    Chen, Libo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 111 - 120
  • [3] Radioiodine refractory differentiated thyroid cancer
    Boudina, Maria
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2023, 26 : 65 - 68
  • [4] THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Huang, W.
    Chen, L.
    Ting, J.
    Cao, V
    Sung, H.
    Yokokura, M.
    Wilson, L.
    VALUE IN HEALTH, 2016, 19 (07) : A886 - A886
  • [5] Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
    Shen, Huize
    Zhu, Rui
    Liu, Yanyang
    Hong, Yangjian
    Ge, Jiaming
    Xuan, Jie
    Niu, Wenyuan
    Yu, Xuefei
    Qin, Jiang-Jiang
    Li, Qinglin
    DRUG RESISTANCE UPDATES, 2024, 72
  • [6] When radioiodine is no longer effective: radioiodine refractory thyroid cancers
    Hadoux, J.
    de la Fouchardiere, C.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2022, 26 (01): : 23 - 28
  • [7] Lenvatinib and radioiodine-refractory thyroid cancers
    Lara Dunn
    James A. Fagin
    Nature Reviews Endocrinology, 2015, 11 : 325 - 327
  • [8] Lenvatinib and radioiodine-refractory thyroid cancers
    Dunn, Lara
    Fagin, James A.
    NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (06) : 325 - 327
  • [9] Redifferentiation of radioiodine-refractory thyroid cancers
    Buffet, Camille
    Wassermann, Johanna
    Hecht, Fabio
    Leenhardt, Laurence
    Dupuy, Corinne
    Groussin, Lionel
    Lussey-Lepoutre, Charlotte
    ENDOCRINE-RELATED CANCER, 2020, 27 (05) : R113 - R132
  • [10] Evaluation of radioiodine treatment of differentiated thyroid cancers with metastases
    Kücük, NÖ
    Aras, G
    Akin, A
    Erbay, G
    Ibis, E
    Kir, KM
    Tokuz, G
    Demir, H
    Gençoglu, EA
    Soylu, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1210 - 1210
12345